Literature DB >> 30459060

Faecal immunochemical tests for haemoglobin (FIT) in the assessment of patients with lower abdominal symptoms: current controversies.

Callum G Fraser1.   

Abstract

Faecal immunochemical tests for haemoglobin (FIT), as an adjunct to clinical information, assist in the triage of patients presenting in primary care with lower abdominal symptoms. Controversy remains regarding whether and which qualitative and quantitative FIT can be used, which groups of patients would benefit most from FIT, whether FIT should be done in primary and/or secondary care, and how FIT should be incorporated into diagnostic pathways. Controversy also exists as to the optimum cut-off used for referral for colonoscopy. A single sample of faeces may be sufficient. Reporting of results requires consideration. FIT provide a good rule in test for colorectal cancer and a good rule out test for significant bowel disease, but robust safety-netting is required for patients with negative results and ongoing symptoms. Risk scoring models have been developed, but their value is unclear as yet. Further evaluation of these topics is required to inform good practice.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Cáncer colorrectal; Enfermedad intestinal importante; Faecal haemoglobin; Faecal immunochemical test; Faecal occult blood test; Hemoglobina fecal; Lower abdominal symptoms; Prueba de sangre oculta en materia fecal; Prueba inmunoquímica fecal; Significant bowel disease; Síntomas abdominales inferiores

Mesh:

Substances:

Year:  2018        PMID: 30459060     DOI: 10.1016/j.gastrohep.2018.09.007

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  6 in total

1.  Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele
Journal:  Ann Clin Biochem       Date:  2021-01-21       Impact factor: 2.057

2.  The EPAGE guidelines are not an effective strategy for managing colonoscopies during the COVID-19 pandemic.

Authors:  Lorena Rodríguez-Alonso; Francisco Rodríguez-Moranta; Sandra Maisterra; Josep M Botargues; Ana Berrozpe; Alexandra Ruíz-Cerulla; Gerard Suris; Blau Camps; Joan B Gornals; Jordi Guardiola
Journal:  Gastroenterol Hepatol       Date:  2021-02-02       Impact factor: 2.102

3.  Cost effectiveness of using Faecal Immunochemical Testing (FIT) as an initial diagnostic investigation for patients with lower gastrointestinal symptoms suggestive of malignancy.

Authors:  C C Kearsey; C Graham; H S Lobb; J Chacko; R Weatherburn; P S Rooney
Journal:  BMC Fam Pract       Date:  2021-05-12       Impact factor: 2.497

4.  Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.

Authors:  Jayne Digby; Shirley Cleary; Lynne Gray; Pooja Datt; David R Goudie; Robert J C Steele; Judith A Strachan; Adam Humphries; Callum G Fraser; Craig Mowat
Journal:  United European Gastroenterol J       Date:  2020-03-16       Impact factor: 4.623

5.  Appraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational study.

Authors:  Jayne Digby; Judith A Strachan; Craig Mowat; Robert J C Steele; Callum G Fraser
Journal:  BMC Gastroenterol       Date:  2019-12-11       Impact factor: 3.067

6.  Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study.

Authors:  Nigel D'Souza; Theo Georgiou Delisle; Michelle Chen; Sally Benton; Muti Abulafi
Journal:  Gut       Date:  2020-10-21       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.